B of A Securities Rates Kymera Therapeutics (KYMR) buy

On June 30, 2026, B of A Securities analyst Tazeen Ahmad reiterated a buy rating on Kymera Therapeutics, Inc. (NASDAQ: KYMR), keeping a price target of $125.00. The call highlights growing confidence in the biopharmaceutical company's targeted protein degradation pipeline, which seeks to treat diseases by using the body's natural systems to remove harmful proteins.

Pipeline Progress Drives the Positive Outlook

Kymera's financial results show a clinical-stage biotech company with growing commercial support. The firm generated $105.0 million in revenue, representing a modest growth rate of 4.66%. While Kymera is not yet profitable—reporting a net loss and a negative earnings per share of -3.25—its research engine remains well-funded. The company is advancing key programs like KT-621, an oral STAT6 degrader in clinical trials for inflammatory diseases like atopic dermatitis and asthma, alongside a strategic partnership with Sanofi S.A. on immunology-inflammation treatments.

Kymera Stock Trades Above Key Moving Averages

Kymera shares closed at $117.75 before the announcement and traded at $114.67 on Tuesday. The stock has shown significant upward momentum over the last year, trading well above its 200-day moving average of $91.61 and right in line with its 50-day moving average of $114.36. This performance places the stock comfortably within the upper half of its 52-week trading range of $50.35 to $130.05, demonstrating sustained investor interest as clinical trials progress.

Recent Earnings

In its latest financial disclosures, Kymera reported total revenue of $105.0 million. Because the company is heavily investing in its clinical trial pipeline, it does not currently have a meaningful price-to-earnings ratio, showing a negative forward P/E of -23.68. The company retains a strong liquidity position, with a current ratio of 10.34 and a quick ratio of 9.97, indicating it has ample cash to fund its near-term operations. Investors are looking ahead to Kymera's next scheduled earnings report on November 3, 2026.

Analysts Set New Price Targets

Wall Street's sentiment toward Kymera is overwhelmingly positive. Out of 22 analyst opinions, the stock holds a consensus recommendation of strong buy, with a mean price target of $138.64. Recent analyst updates show even higher expectations. On October 9, 2026, Raymond James initiated coverage with an Outperform rating and a $140.00 price target. Citigroup maintained a Buy rating on October 5, 2026, raising its target to $150.00. Stifel also backed the stock on September 22, 2026, with a Buy rating and a $152.00 target, while B of A Securities later raised its own target to $144.00 on September 14, 2026.

Inside Kymera's Protein Degradation Technology

Kymera Therapeutics is a Watertown, Massachusetts-based biotechnology firm focused on discovering and developing small molecule medicines. Unlike traditional drugs that temporarily block disease-causing proteins, Kymera's platform degrades these proteins entirely by harnessing the body's natural cellular cleanup machinery. This novel approach has broad applications across both immunology and oncology, particularly for challenging conditions that have been difficult to treat with conventional therapies.

What to Watch at Kymera Therapeutics, Inc.

As Kymera moves closer to its next earnings report in November, investors will be watching for clinical data updates from its Phase 2 trials for KT-621. Continued progress in its partnership with Sanofi could also trigger milestone payments, which would further bolster the company's balance sheet. While analyst ratings provide helpful context on market expectations, they represent opinions that can change as new clinical data emerges.